Saturday 17 October 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.
0.92
0.11
−10.68%
Follow ISPC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 3,800.00 | 936.00 | 325.60 | 104.88 | 10.40 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 23,184.00 | 7,840.00 | 1,636.80 | 488.00 | 135.20 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 46 | 59 | 75 | 53 | 24 | 7 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.18 | 0.19 | 0.14 | 0.19 | 0.39 | 0.28 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 4 | 4 | 8 | 11 | 10 | 10 | 9 | 2 | ||||
| Gross margin, % | — | — | 46.24 | 50.50 | 56.19 | 52.86 | 54.27 | 51.45 | 42.93 | 1.25 | |||||
| EBT | — | — | (5) | (5) | (5) | (9) | (10) | (11) | (12) | (10) | |||||
| EBT margin, % | — | — | (124.56) | (113.63) | (56.84) | (80.48) | (98.50) | (111.80) | (134.51) | (543.68) | |||||
| Net income | — | 0 | (5) | (5) | (5) | (9) | (10) | (11) | (12) | (10) | |||||
| Depreciation | — | — | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.67 | 3,582.00 | 6,820.08 | 2,062.09 | 937.14 | 878.60 | 521.97 | 16.76 | ||||
| Earnings | — | — | (0.81) | (4,039.80) | (3,976.14) | (1,672.00) | (928.00) | (984.00) | (703.20) | (91.20) | |||||
| Cash flow | — | — | (0.41) | (2,233.25) | (240.33) | (1,975.63) | (524.12) | (513.95) | (464.25) | (36.84) | |||||
| Capex | — | — | 0.00 | (2,435.25) | (1,837.33) | (383.94) | (555.58) | (419.88) | (38.47) | (8.69) | |||||
| Free cash flow | — | — | (0.41) | (4,668.50) | (2,077.67) | (2,359.57) | (1,079.69) | (933.82) | (502.72) | (45.54) | |||||
| Book value | — | — | (2.81) | (9,621.42) | (13,420.75) | 5,516.96 | 1,829.66 | 862.04 | 186.01 | 26.83 | |||||
| Shares, m | — | — | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 0.73 | 0.73 | 0.73 | 3.03 | 1.20 | 0.48 | 0.20 | 0.62 | |||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 1.13 | 0.62 | 0.49 | 0.57 | 0.39 | |||||
| EV/Sales | — | — | 1.87 | 1.87 | 1.87 | 0.85 | (0.02) | 0.24 | 0.28 | (1.59) | |||||
| EV/FCF | — | — | (28.11) | (28.11) | (28.11) | (0.74) | 0.01 | (0.18) | (0.24) | 0.41 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | (3) | 0 | (11) | (6) | (6) | (8) | (4) | ||||
| Capex | — | — | (1) | (3) | (2) | (2) | (6) | (5) | (1) | (1) | |||||
| Free cash flow | — | — | (3) | (6) | (2) | (13) | (12) | (11) | (9) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (9) | (14) | (19) | 30 | 15 | 2 | (2) | 1 | ||||
| Total debt | — | — | 18 | 11 | 0 | 3 | 0 | — | — | — | |||||
| Net debt | — | — | 17 | 11 | (1) | (24) | (15) | (5) | (2) | (7) | |||||
| Shareholders’ equity | — | — | (18) | (12) | (16) | 30 | 20 | 10 | 3 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (264.41) | (114.47) | (89.25) | (42.75) | (33.96) | (54.90) | (99.31) | (111.09) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (67.64) | (127.31) | (147.42) | (555.29) | 0.00 | |||||
| ROE | — | — | 25.99 | 22.98 | 18.61 | (713.06) | (40.90) | (73.87) | (191.51) | (327.78) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
iSpecimen Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NDRA ENDRA Life Sciences Inc. | $7.7M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XWEL XWELL, Inc. | $7.5M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $5.1M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| NOTVQ Inotiv, Inc. | $2.8M | — (loss-making) | — (loss-making) | −5.37% (below 0%: shrinking) | n/m | +82.66% (above 0%: growing) | 20.95% | (16.41%) | Compare |
| ISPC iSpecimen Inc. | $2.6M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| PRPH ProPhase Labs, Inc. | $1.2M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 22.35% | (261.62%) | Compare |
| Median of peers | $4.2M | — | — | −6.22% | — | +19.96% | 21.65% | (155.23%) |
iSpecimen Inc. (ISPC) key facts
- Concern: iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- iSpecimen Inc. (ISPC) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ISPC traded at $0.92, a market capitalization of $2.6 million.
- Return on equity was −327.8% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −14.80 (distress zone) for fiscal 2025.